Literature DB >> 10426302

COX-2: promoting tolerance.

O Morteau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426302     DOI: 10.1038/11301

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  5 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.

Authors:  O Morteau; S G Morham; R Sellon; L A Dieleman; R Langenbach; O Smithies; R B Sartor
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: implications for viral transmission.

Authors:  M Moriuchi; H Inoue; H Moriuchi
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut.

Authors:  Kenji Kabashima; Tomomi Saji; Takahiko Murata; Miyako Nagamachi; Toshiyuki Matsuoka; Eri Segi; Kazuhito Tsuboi; Yukihiko Sugimoto; Takuya Kobayashi; Yoshiki Miyachi; Atsushi Ichikawa; Shuh Narumiya
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

5.  Nuclear factor kappa B is activated in small intestinal mucosa of celiac patients.

Authors:  Maria Chiara Maiuri; Daniela De Stefano; Guido Mele; Simona Fecarotta; Luigi Greco; Riccardo Troncone; Rosa Carnuccio
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.